Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.